COMP <GO>
OPCH vs JNJ // GROSS PROFIT MARGIN
Option Care Health Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: OPCH 6
— JNJ 7
▲ GROSS PROFIT MARGIN LEADER: JNJ
LAST: $31.83 (-0.06%) • MKT CAP: $4.77B
gross-margins
19.30%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
gross-margins
67.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OPCH VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | OPCH | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 19.30% | 67.90% | -48.60 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.90% | 25.50% | -13.60 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 15.3x | 18.5x | -3.20 | OPCH | /valuation <GO> |
| Free Cash Flow Yield | 4.55% | 2.97% | +1.58 | OPCH | /fcf-yield <GO> |
| Operating Margin | 6.00% | 34.70% | -28.70 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 3.70% | 28.50% | -24.80 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 13.00% | 6.00% | +7.00 | OPCH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.81 | 5.59 | -1.78 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 7.20% | 0.00 | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 84.3 | 60.4 | +23.91 | OPCH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 1.08 | +0.02 | OPCH | /macro-sensitivity <GO> |
| Forward P/E Multiple | 19.3x | 23.0x | -3.70 | OPCH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.77B | $662.49B | -$657.72B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | OPCH REV | JNJ REV | OPCH GROSS % | JNJ GROSS % | OPCH FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.65B | $94.19B | 19.3% | 67.9% | $217.1M | $19.70B |
| FY 2024 | $5.00B | $88.82B | 20.3% | 69.1% | $287.8M | $19.84B |
| FY 2023 | $4.30B | $85.16B | 44.0% | 44.0% | $177.7M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OPCH // BETA 1.10
JNJ // BETA 1.08